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Hodgkin's disease (HD) is often described as a lymphoid
disorder associated with T cell hyporesponsiveness even in
the early stages of the disease (Kaplan, 1981; Kumar &
Penny, 1982). Our earlier studies revealed that HD patients
had normal levels of T and B cells in circulation, while they
exhibited decreased mitogen (PHA) responsiveness as
assessed by 3H-TdR incorporation as well as by T cell colony
formation (Moghe et al., 1980; Mukhopadhyaya et al., 1983).
Activated lymphocytes from HD patients showed reduced
levels of Tac + cells and reduced IL-2 production (Joshi et
al., 1987; Mukhopadhyaya et al., 1987a). However, upon
addition of exogenous IL-2, lymphocytes from about half of
the HD patients showed an increase in 3H-TdR incorporation
but none showed an increase in T cell colony formation
(Mukhopadhyaya et al., 1987b). Other investigators have also
reported similar abnormalities in IL-2 mediated events in T
cell activation in HD (Ford et al., 1984; Soulillou et al., 1985;
Zamkoff et al., 1985).
The biological effect of IL-2 depends upon its binding to
high affinity (HA) IL-2 receptors (IL-2R) on the membranes
of activated cells, and internalisation of the complex (Fujii et
al., 1986; Lowenthal & Greene, 1987; Robb & Gfeene, 1987).
It is now well documented that IL-2R has a double chain
molecular structure. The 13 chain (a Tac molecule) of M,
55,000 has a low affinity for IL-2 (Kd10-8M) and displays a
fast rate of association and dissociation. The a-chain of Mr
75,000 with intermediate affinity (Kd-5 x 10-10 to 10-9M)
has a slower rate of association and dissociation. A non-
covalent association of these two chains makes a high affinity
receptor (Kd-10-IlM) capable of signal transduction (Wang
& Smith, 1987; Lowenthal & Greene, 1987). Although the
Tac molecule (p chain) is the first to interact with IL-2, this
interaction does not induce internalisation of the complex, a
prerequisite for signal transduction.
In case of HD, the evidence gathered so far suggests that,
although the proportion of Tac + cells is less in activated
lymphocyte populations in HD, the deficit is not propor-
tional to the pronouned defect in the proliferative responses
(Mukhopadhyaya et al., 1987a). Also, addition of exogenous
IL-2 did not restore fully the ability of the lymphocytes to
proliferate and to form colonies (Mukhopadhyaya et al.,
1987b). It was therefore felt that as well as the number of
Tac antigen-bearing cells per se, the number of HA IL-2R
per cell (which are responsible for triggering post-binding
events) may be more important in the T cell hyporespon-
siveness in HD.
In the present investigations, we have therefore analysed
the low and high affinity IL-2R (LA IL-2R and HA IL-2R)
on PHA activated lymphocytes from the peripheral blood
(PBL) of patients with HD and healthy donors, using 1251I
labelled recombinant IL-2 (received as a kind of gift from
Cetus Corporation, USA; Doyle et al., 1985) as a ligand.
Freshly diagnosed, untreated HD patients, in the age group
of 18-58 years (20 males and 5 females), and belonging to all
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stages and grades of the diseases were included in the studies.
Laboratory personnel (age group 20-35 years) constituted
the control group. PBL were separated on a Ficoll-Hypaque
gradient, washed and cultured in DMEM (Gibco) supp-
lemented with antibiotics and 10% human blood group AB
serum. Cells (2.5 x 106ml-') were stimulated with 0.5%
PHA-M (Gibco, v/v) for 72 h at 37C in a humidified 5%
CO2 atmosphere. The blasts thus obtained were used for
further studies.
Recombinant IL-2 was labelled with 125I (Amersham, UK)
by the method described by Robb et al. (1985), with some
modifications. IL-2, Na'251I and chloramaine-T were used at
the molar ratios of 1:27.8:5.1. The reaction was carried out at
room temperature for 5 min and was stopped using Na2S205
(0.278 mM). Free iodine was separated from '251I-IL-2 on a
Sephadex G25 column, eluted with phosphate buffered saline
containing 0.1% BSA and 1.5% acetic acid (final pH 3.9).
'25I-IL-2 with specific activity above 20,000 c.p.m. ng-1 was
used for the experiments. Specificity of binding of '251-IL-2
was tested by assessing the radioactivity bound to PHA
induced blasts from PBL of two healthy donors as a function
of cell number and also by determining the inhibition of
binding of '25I-IL-2 by increasing amounts of unlabelled IL-2
(Figure 1). The bioactivity of '251-IL-2 was assessed by its
capacity to induce proliferation of CTLL (Gillis et al., 1978).
Proliferation of CTLL induced by '251I-IL-2 was 70-80% of
that induced by unlabelled IL-2.
For experiments proper, the 251I-IL-2 binding assay was
performed on PHA transformed blasts from PBL of HD
patients and healthy donors, as described earlier (Fujii et al.,
1986). Non-specific binding was determined in the presence
of 100-fold molar excess of unlabelled IL-2 and was sub-
tracted before transforming the binding data into Scatchard
plots. Dissociation constants (Kd) and number of receptors
per cell were estimated from the Scatchard plots. Wherever
possible, quantitation of PHA induced blasts (using Giemsa
stained cytospin smears) and cell proliferation using 3H-TdR
incorporation were studied simultaneously in order to com-
pare the data with the IL-2R status.
The results indicated that lymphocytes from HD patients
show significantly lower PHA induced proliferation and per
cent blast formation as compared to lymphocytes from heal-
thy donors (Table I), while, as reported earlier (Joshi et al.
1987), the percentage of Tac + cells in PHA activated HD
PBL was 42.3 ± 11.2 (P<0.05) as compared to the value for
healthy donors of 52.2 ± 14.1. The number and affinity of
LA IL-2R on PHA blasts of HD patients and healthy donors
were comparable (Table I). It was interesting to note that the
Kd value, which indicates half the maximal concentration of
the ligand (IL-2) for saturation of the receptors, was
significantly higher for HA IL-2R in HD patients than for
HA IL-2R in healthy donors. The requirement for higher
concentration of IL-2 reflects the lower affinity of the recep-
tors for the ligand. However, the number of receptors per cell
did not differ significantly between these two groups.
In a few patients and healthy donors, where we have been
able to investigate proliferation and '25I-IL-2 binding simul-
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taneously (Figure 2), it was seen that the Kd values of HA
IL-2R appear to be inversely proportional to the 3H-TdR
incorporation with a correlation coefficient of -0.488
(P<0.05).
Anti-Tac monoclonal antibodies have often been used to
study the IL-2R status in malignancies inlcuding HD (Piz-
zolo et al., 1984; Joshi et al., 1987; Zamkoff et al., 1985).
Radiolabelled IL-2 binding analysis, which dissects out the
proportions of high and low affinity IL-2R per cell, has been
performed only in the case of IL-2R expressing leukaemic
cells by Uchiyama (1988) and recently by Nagel et al. (1989).
The latter have studied the status of HA IL-2R on PHA
activated cells from aged individuals to correlate the findings
with reduced T cell responsiveness, in ageing. In the present
report, we have studied the relationship of proliferation and
status of HA IL-2R on mitogen activated PBL and HD.
Several factors need to be considered in explaining our
data. Abnormal ratios of CD4/CD8 cells reported in HD
(Romagnani et al., 1985) may influence the IL-2R status of
activated PBL in this disease. However, our earlier data and
those of others (Gulwani et al., 1985; Posner et al., 1981) do
not show significant deviations in T cell subsets in HD.
Contribution of other lymphocyte populations expressing IL-
2R, such as B cells and NK cells, to the deviations in IL-2R
status in HD is also incertain. Normal proportions of B cells
have previously been demonstrated in HD (Case et al., 1976;
Moghe et al., 1980). Recently, we have shown that the
proportion of HNK-1 + cells, which represent a subset of
NK cells, does not vary between the PBL of HD patients and
those from healthy donors (Rajaram et al., personal com-
munication).
Our data have shown that activated PBL from HD have
an adequate number of HA IL-2R but that they display
elevated dissociation constants and a decreased proliferative
response. Nagel et al. (1989) have also found decreased pro-
liferative responses of PHA activated PBL from aged individ-
uals, although the lymphocytes had comparable numbers of
HA IL-2R and Kd values to that of PBL from young individ-
uals. They have tried to interpret their data on the basis of
abnormal functions of the receptors in terms of their ability
to transduce signals or failure to regulate the expression of
other genes such as the transferrin receptor gene.
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Figure I Assessment of binding of '251-IL-2. The top panel
indicates increase in the radioactivity bound to mitogen activated
lymphocytes from two healthy donors with increasing number of
cells. The lower panel depicts displacement of radiolabelled IL-2
(0.5 ng) with increasing concentrations of unlabelled IL-2 in com-
petition RIA using PHA activated lymphocytes from a healthy
donor.
Table I IL-2 binding and transformation ofPHA activated PBL from
HD patients and healthy donors
Parameter Healthy donors HD patients
Proliferation 95,133 ± 13,037 42,678 ± 4,651
(n = 10) (n = 23, P<0.001)
%blasts 58 ± 3.6 43 ± 3.5
(n= 15) (n= 16, P<0.01)
Low affinity IL-2R
Kd(X 1O-9M) 5.67 3.17 10.13 ± 6.37
(n= 15) (n = 12, N.S.)
No. per cell 17,018 ± 3,791 13,591 ± 4,502
(n = 15) (n = 12, n.s.)
High affinity IL-2R
Kd (X 10 -2M) 40.41 + 7.17 107.59 ± 20.58
(n = 18) (n = 14, P<0.01)
No. per cell 2,808 ± 280 2,243 ± 342
(n = 18) (n = 14, n.s.)
3H-TdR incorporation: net mean c.p.m. ± s.e. (no. of individuals
studied, P value).
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Figure 2 Simultaneous assessment of proliferation (3H-TdR
incorporation) and affinity (Kd) of high affinity IL-2R on PHA
activated lymphocytes from healthy donors (A) and HD patients
(A).
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Our observations indicate the possibility of structural
heterogeneity in HA IL-2R leading to T cell functional
defects in HD. It is possible that a post-binding event such as
internalisation of IL-2 and IL-2 complex leading to signal
transduction (Fujii et al., 1986; Robb & Greene, 1987) may
be abnormal in such situations. We are currently conducting
studies on internalisation of '25I-IL-2 by activated PBL from
HD in comparison with that by activated PBL from healthy
donors, which may shed some light on this possibility.
References
CASE, D.C., HANSEN, J.A., CORRALES, E. & 4 others (1976). Com-
parison of multiple in vivo and in vitro parameters in untreated
patients with Hodgkin's disease. Cancer, 38, 1807.
DOYLE, M.V., LEE, M.T. & FONG, W. (1985). Comparison of the
biological activities of human recombinant interleukin-2 and
native interleukin-2. J. Biol. Resp. Mod., 4, 96.
FORD, R.J., TSAO, J., KOUTTAB, N.M., SAHASRABUDDHE, C.G. &
MEHTA, S.R. (1984). Association of an interleukin abnormality
with the T cell defect in Hodgkin's disease. Blood, 64, 386.
FUJII, M., SUGAMURA, D., SANO, K., NAKAI, M., SUGITA, K. &
HINUMA, Y. (1986). High-affinity receptor mediated internaliza-
tion and degradation of interleukin-2 in human T cells. J. Exp.
Med., 163, 550.
GILLIS, S., FERM, M.M., OU, W. & SMITH, K.A. (1978). T-cell growth
factor: parameters of production and quantitative microassay for
activity. J. Immunol., 120, 2027.
GULWANI, B.N., ADVANI, S.H. & GANGAL, S.G. (1985). Distribution
of subpopulations of T lymphocytes in Hodgkin's disease. Neo-
plasma, 32, 239.
JOSHI, N.N., MUKHOPADHYAYA, R., ADVANI, S.H. & GANGAL, S.G.
(1987). Production of interleukin-2 and expression of Tac antigen
in Hodgkin's disease. Cancer Detect. Prevent., suppl. 1, 137.
KAPLAN, H.S. (1981). Hodgkin's disease: biology treatment, prog-
nosis. Blood, 57, 813.
KUMAR, R. & PENNY, R. (1982). Cell-mediated immune deficiency in
Hodgkin's disease. Immunol. Today, 3, 269.
LOWENTHAL, J.W. & GREENE, W.C. (1987). Contrasting Interleukin-
2 binding properties of the a (p55) and P (p70) protein subunits
of the human high-affinity interleukin-2 receptor. J. Exp. Med.,
166, 1156.
MOGHE, M.V., ADVANI, S.H. & GANGAL, S.G. (1980). Demonstra-
tion of inhibitory factors affecting cell-mediated immunity in
patients with Hodgkin's disease. Eur. J. Cancer, 16, 937.
MUKHOPADHYAYA, R., ADVANI, S.H. & GANGAL, S.G. (1983).
Impairment of T lymphocyte colony formation in Hodgkin's
disease: effect of soluble inhibitory factors on normal T lym-
phocyte colony formation potential. Acta Haematol., 70, 357.
MUKHOPADHYAYA, R., ADVANI, S.H. & GANGAL, S.G. (1987a).
Functional evaluation of T-lymphocytes from peripheral blood
and spleens in Hodgkin's disease. Br. J. Cancer, 56, 800.
MUKHOPADHYAYA, R., ADVANI, S.H. & GANGAL, S.G. (1987b).
Effect of exogenous interleukins on in vitro responses of T lym-
phocytes from patients with Hodgkin's disease. Cancer Detect.
Prevent., 10, 445.
NAGEL, J.E., CHOPRA, R.K., POWERS, D.C. & ADLER, W.H. (1989).
Effect of age on the human high affinity interleukin-2 receptor of
phytohaemagglutinin stimulated peripheral blood lymphocytes.
Clin. Exp. Immunol., 75, 286.
PIZZOLO, G., CHILOSI, M., SEMENZATO, G. & 4 others (1984).
Immunohistological analysis of Tac antigen expression in tissues
involved by Hodgkin's disease. Br. J. Cancer, 50, 415.
POSNER, M.R., REINHERZ, E.L., BREARD, J., NADLER, L.M.,
ROSENTHAL, D.S. & SCHOLOSSMAN, S.F. (1981). Lymphoid sub-
populations of peripheral blood and spleen in untreated Hodg-
kin's disease. Cancer, 48, 1170.
ROBB, R.J. & GREENE, W.C. (1987). Internalization of IL-2 is
mediated by the P chain of the high affinity interleukin-2 recep-
tor. J. Exp. Med., 165, 1201.
ROBB, R.J., MAYER, P.C. & GARLICK, R. (1985). Retention of
biological activity following radioiodination of human
interleukin-2: comparison with biosynthetically labelled growth
factor in receptor binding assays. J. Immunol. Methods, 81, 15.
ROMAGNANI, S., FERRINI, P.L.R. & RICCI, M. (1985). The immune
derangement in Hodgkin's disease. Semin. Hematol., 22, 41.
SOULILLOU, J.P., DOUILLARD, J.Y., VIE, H. & 4 others (1985).
Defects in lectin induced Interleukin-2 (IL-2) production by
peripheral blood lymphocytes of patients with Hodgkin's disease.
Eur. J. Cancer Clin. Oncol., 21, 935.
UCHIYAMA, T. (1988). Abnormal interleukin-2 receptor expression
in adult T-cell leukemia. In Interleukin 2, Smith, K.A. (ed.)
p. 179. Academic Press: New York.
WANG, H.M. & SMITH, K.A. (1987). The interleukin-2 receptor: func-
tional consequences of its bimolecular structure. J. Exp. Med.,
166, 1055.
ZAMKOFF, K.W., REEVES, W.G., PAOLOZZI, F.P., POIESZ, S.J.,
COMIS, R.L. & TOMAR, R.H. (1985). Impaired Interleukin regula-
tion of the phytohaemagglutin response in Hodgkin's disease.
Clin. Immunol. Immunopathol., 35, 111.